Recon: J&J, Protagonist tout phase 3 study wins for oral IL-23 therapy; Bayer buys Japanese rights to Cytokinetics’ heart drug
ReconJason Scott
Biologics/ biosimilars/ vaccinesMedical DevicesPharmaceuticalsRegulatory Intelligence/PolicyReconJason ScottBiologics/ biosimilars/ vaccinesMedical DevicesPharmaceuticalsRegulatory Intelligence/Policy